Search Result

Results for "

m6A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Deaminase (1) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (10) Autophagy (2) Bcl-2 Family (1) Caspase (1) DNA/RNA Synthesis (1) Endogenous Metabolite (1) Fat Mass and Obesity-associated Protein (FTO) (4) Ferroptosis (2) Glutathione Peroxidase (2) Heme Oxygenase (HO) (2) iGluR (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (1) Keap1-Nrf2 (2) METTL3 (3) PARP (1) PROTACs (2) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Small Interfering RNA (siRNA) (5) TGF-β Receptor (2) YTHDF (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Infection (1) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (2) siRNAs (5)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131871

Ethyl LipotF	Fat Mass and Obesity-associated Protein (FTO)	Cancer
Ethyl LipotF is a selective FTO inhibitor that significant increases modified N6-methyladenosine (m6A) levels in HeLa cells in a concentration-dependent manner .

HY-165422

ALKBH5-IN-3	Anaplastic lymphoma kinase (ALK)	Cancer
ALKBH5-IN-3 (Compound 20m) is a potent and selective ALKBH5 inhibitor, with an IC₅₀ of 21 nM. ALKBH5-IN-3 could efficiently stabilize ALKBH5 in HepG2 cells and increase m6A level in intact cells .

HY-153274

CWI1-2 3 Publications Verification	Apoptosis	Cancer
CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects .

HY-153274A

CWI1-2 hydrochloride 3 Publications Verification	Apoptosis	Cancer
CWI1-2 hydrochloride is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects .

HY-N0086R

N6-Methyladenosine (Standard) 6-Methyladenosine (Standard); N-Methyladenosine (Standard)	Endogenous Metabolite Influenza Virus Reference Standards	Infection
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .

HY-137187

FB23 1 Publications Verification	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FB23 is a potent and selective FTO demethylase inhibitor with an IC₅₀ of 60 nM. FB23 directly binds to FTO and selectively inhibits FTO's mRNA N ⁶-methyladenosine (m6A) demethylase activity .

HY-159604

METTL3-IN-9	METTL3	Cancer
METTL3-IN-9 (compound C3) is an inhibitor of methyltransferase-like METTL3, an RNA methyltransferase that catalyzes the N6-methyladenosine (m6A) modification of mRNA in eukaryotic cells .

HY-W173146

ALKBH5-IN-4	DNA/RNA Synthesis	Cancer
ALKBH5-IN-4 (compound 3) is a RNA m6A demethylase ALKBH5 inhibitor with an IC₅₀ of 0.84 μM. ALKBH5-IN-4 shows inhibitory effect on leukemia cells_[1].

HY-156773

STM3006	Apoptosis METTL3	Cancer
STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC₅₀: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results .

HY-174873

AF151	PROTACs METTL3 Apoptosis Bcl-2 Family	Cancer
AF151 is a METTL3 PROTAC degrader with the DC₅₀ of 0.43 μM in MOLM-13 cells. AF151 inhibits cell growth by significantly degrading METTL3 protein and reducing m6A levels. AF151 can induce cell apoptosis and reduce the level of Bcl-2 protein. AF151 can be used for research on cancer such as acute myeloid leukemia (AML). (Pink: METTL3 Ligand (HY-174874); Blue: VHL Ligand (HY-125845); Black: Linker; VHL Ligand+Linker (HY-174875)) .

HY-21197

Perfluoroenanthic acid Perfluoroheptanoic acid; Tridecafluoroheptanoic acid; PFHpA	iGluR	Neurological Disease
Perfluoroenanthic acid (Perfluoroheptanoic acid) is a type of perfluoroalkyl substance (PFAS) that can negatively impact the development of seminiferous tubules and m6A RNA methylation in the testes of offspring mice when exposed during pregnancy, consequently disrupting spermatogenesis and leading to reproductive toxicity. Perfluoroenanthic acid alters the morphology of dendritic spines and synaptic formation in primary cortical neuron cultures, enhancing neuronal activity and synaptic transmission, and increasing the expression of excitatory synapse-related proteins Synaptophysin and PSD95 .

HY-E70582

E.coli tRNA adenosine deaminase	Adenosine Deaminase	Others
E.coli tRNA adenosine deaminase is derived from E.coli and is an adenine deaminase that can deaminate adenine in single-stranded RNA (ssRNA, mainly the loop region within tRNA) or double-stranded RNA (dsRNA), but has no deamination activity on DNA. E.coli tRNA adenosine deaminase is a protein-modified mutant of adenine deaminase, which can efficiently deaminate adenine in ssDNA and can be applied to adenine base editors (ABE) and RNA m6A methylation sequencing .

HY-173008

YTHDF2-IN-1	Apoptosis YTHDF	Cancer
YTHDF2-IN-1 (Compound CK-75) is the inhibitor for YT521-B homology domain family 2 YTHDF2 (K_d=26.2 μM), that blocks the interaction between YTHDF2 and m6A RNA. YTHDF2-IN-1 inhibits the colony formation of JAR cells, exhibits antiproliferative activity in a variety of cancer cells (IC₅₀ in micromolar levels), arrests the cell cycle at G0/G1 phase, induces apoptosis in K562 .

HY-175885

PROTAC FTO degrader 1	PROTACs Fat Mass and Obesity-associated Protein (FTO) Apoptosis Caspase PARP YTHDF	Cancer
PROTAC FTO degrader 1 is a Fat Mass and Obesity-associated Protein (FTO) PROTAC degrader. PROTAC FTO degrader 1 selectively degrades FTO depending on VHL E3 ligase and ubiquitin-proteasome system. PROTAC FTO degrader 1 can increase m₆A modifications on mRNAs associated with ribosome biogenesis and promote their YTHDF2-mediated decay. PROTAC FTO degrader 1 can inhibit cancer cells proliferation and induce apoptosis. PROTAC FTO degrader 1 can be used for the research of cancer, such as acute myeloid leukemia (AML) . (Structure Note: Pink: FTO ligand (HY-175886); Blue: VHL ligand (HY-112078); Black: linker (HY-W002042); VHL ligand-Linker: (HY-139218))

HY-N0353

Curdione 1 Publications Verification (+)-Curdione	Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)	Cardiovascular Disease Neurological Disease Cancer
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression ^[6] .

HY-N0353R

Curdione (Standard) (+)-Curdione (Standard)	Reference Standards Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)	Others
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression ^[6] .

HY-RS29055

Gpm6a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Gpm6a Rat Pre-designed siRNA Set A contains three designed siRNAs for Gpm6a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Gpm6a Rat Pre-designed siRNA Set A Gpm6a Rat Pre-designed siRNA Set A

HY-RS22535

Gpm6a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Gpm6a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gpm6a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Gpm6a Mouse Pre-designed siRNA Set A Gpm6a Mouse Pre-designed siRNA Set A

HY-RS05643

GPM6A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
GPM6A Human Pre-designed siRNA Set A contains three designed siRNAs for GPM6A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

GPM6A Human Pre-designed siRNA Set A GPM6A Human Pre-designed siRNA Set A

HY-RS16508

Mettl3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mettl3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mettl3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mettl3 Mouse Pre-designed siRNA Set A Mettl3 Mouse Pre-designed siRNA Set A

HY-W026109

FTO-IN-12	Fat Mass and Obesity-associated Protein (FTO)	Neurological Disease
FTO-IN-12 (Compound 2) is an inhibitor of fat mass and obesity-related protein (FTO). K_d and IC₅₀ values are 185 nM and 1.46 μM, respectively. FTO-IN-12 can be used in the study of neurodegenerative diseases .

HY-RS08364

METTL3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
METTL3 Human Pre-designed siRNA Set A contains three designed siRNAs for METTL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

METTL3 Human Pre-designed siRNA Set A METTL3 Human Pre-designed siRNA Set A

HY-127103

FB23-2 Maximum Cited Publications 22 Publications Verification	Apoptosis	Cancer
FB23-2 is a potent and selective inhibitor of mRNA N ⁶-methyladenosine (m ⁶A) demethylase FTO, with an IC₅₀ of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML) .

HY-155489

DDO-2728 1 Publications Verification	Anaplastic lymphoma kinase (ALK) Apoptosis	Cancer
DDO-2728 (compound 19) is a selective AlkB homologue 5 (ALKBH5) inhibitor with an IC₅₀ of 2.97 μM. DDO-2728 increases the abundance of N ⁶ methyladenosine (m ⁶A) modifications, inducing cell apoptosis and cycle arrest. DDO-2728 suppresses tumor growth in the MV4 11 xenograft model with favorable safety profile, shows the potential of targeting ALKBH5 in cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0086R

N6-Methyladenosine (Standard) 6-Methyladenosine (Standard); N-Methyladenosine (Standard)	Natural Products Microorganisms Source classification Endogenous metabolite	Endogenous Metabolite Influenza Virus Reference Standards
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .

HY-N0353

Curdione 1 Publications Verification (+)-Curdione	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Other Diseases Curcuma phaeocaulis Valeton Plants Disease Research Fields Zingiberaceae	Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression ^[6] .

HY-N0353R

Curdione (Standard) (+)-Curdione (Standard)	Terpenoids Sesquiterpenes Source classification Curcuma phaeocaulis Valeton Plants Zingiberaceae	Reference Standards Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression ^[6] .

Cat. No.	Compare	Product Name	Species	Source

HY-P701888

	FTO Protein, Human (His) FTO; Alpha-ketoglutarate-dependent dioxygenase FTO; Fat mass and obesity-associated protein; U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; U6 small nuclear RNA N(6)-methyladenosine-demethylase FTO; mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; m6A(m)-demethylase FTO; mRNA N(6)-methyladenosine demethylase FTO; tRNA N1-methyl adenine demethylase FTO	Human	E. coli
	FTO protein is an RNA demethylase that regulates fat mass, lipogenesis, and energy homeostasis by targeting N(6)-methyladenosine in mRNA. It also demethylates m6A in U6 snRNA and m6A(m) in 5'-cap, affecting mRNA stability. FTO Protein, Human (His) is the recombinant human-derived FTO protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83709

	m6A Antibody (YA3446) m6A antibody; N6-methyladenosine antibody	ELISA, Dot Blot	Species independent
	m6A Antibody (YA3446) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to m6A.